Evidence map›Paper›PMID 34516618›Full record

ArticleBlood advances2021

Expanding the genetic spectrum of TUBB1-related thrombocytopenia.

Verónica Palma-Barqueros, Loredana Bury, Shinji Kunishima, María Luisa Lozano, Augustín Rodríguez-Alen, Nuria Revilla, Natalia Bohdan, José Padilla, María P Fernández-Pérez, María Eugenia de la Morena-Barrio and 10 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Blood advances, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 32 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. The co-inheritance of twoHaematologica · 2026
    Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 9 institutions in 3 countries.

Verónica Palma-BarquerosServicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, Instituto Murciano de Investigación Biosanitaria-Arrixaca, Centro de Investigacién Biomódica en Red de Enfermedades Raras-U765, Murcia, Spain.ORCID 0000-0002-5699-0053
Loredana BuryDepartment of Medicine and Surgery, University of Perugia, Perugia, Italy.ORCID 0000-0003-0333-0948
Shinji KunishimaDepartment of Medical Technology, Gifu University of Medical Science, Seki, Japan.ORCID 0000-0001-9212-0082
María Luisa LozanoServicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, Instituto Murciano de Investigación Biosanitaria-Arrixaca, Centro de Investigacién Biomódica en Red de Enfermedades Raras-U765, Murcia, Spain.ORCID 0000-0003-3148-7037
Augustín Rodríguez-AlenServicio de Hematología y Hemoterapia, Hospital Virgen de la Salud, Complejo Hospitalario de Toledo, Toledo, Spain.ORCID 0000-0003-3583-2977
Nuria RevillaServicio de Hematología, Hospital Universitario Hospital Universitario Ramón y Cajal, Madrid, Spain.ORCID 0000-0002-0995-1043
Natalia BohdanServicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, Instituto Murciano de Investigación Biosanitaria-Arrixaca, Centro de Investigacién Biomódica en Red de Enfermedades Raras-U765, Murcia, Spain.
José PadillaServicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, Instituto Murciano de Investigación Biosanitaria-Arrixaca, Centro de Investigacién Biomódica en Red de Enfermedades Raras-U765, Murcia, Spain.ORCID 0000-0003-1599-7870
María P Fernández-PérezServicio de Hematología, Hospital Universitario Hospital Universitario Ramón y Cajal, Madrid, Spain.ORCID 0000-0003-4916-1959
María Eugenia de la Morena-BarrioServicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, Instituto Murciano de Investigación Biosanitaria-Arrixaca, Centro de Investigacién Biomódica en Red de Enfermedades Raras-U765, Murcia, Spain.ORCID 0000-0001-7426-4947
Ana Marín-QuilezInstituto de Investigación Biomédica de Salamanca, Instituto de Biología Molecular y Celular del Cáncer, Centro de Investigación del Cáncer, Universidad de Salamanca-Consejo Superior de Investigaciones Científicas.ORCID 0000-0002-2005-1919
Rocío BenitoInstituto de Investigación Biomédica de Salamanca, Instituto de Biología Molecular y Celular del Cáncer, Centro de Investigación del Cáncer, Universidad de Salamanca-Consejo Superior de Investigaciones Científicas.
María F López-FernándezServicio Hematología y Hemoterapia, Complejo Hospitalario Universitario A Coruña, Spain.ORCID 0000-0003-2492-1843
Shally MarcelliniServicio Hematología, Hospital General, Segovia, Spain; and.ORCID 0000-0002-6057-6058
Ana Zamora-CánovasServicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, Instituto Murciano de Investigación Biosanitaria-Arrixaca, Centro de Investigacién Biomódica en Red de Enfermedades Raras-U765, Murcia, Spain.ORCID 0000-0002-5562-203X
Vicente VicenteServicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, Instituto Murciano de Investigación Biosanitaria-Arrixaca, Centro de Investigacién Biomódica en Red de Enfermedades Raras-U765, Murcia, Spain.ORCID 0000-0002-4278-3264
Constantino MartínezServicio de Hematología, Hospital Universitario Hospital Universitario Ramón y Cajal, Madrid, Spain.ORCID 0000-0002-2976-2354
Paolo GreseleDepartment of Medicine and Surgery, University of Perugia, Perugia, Italy.ORCID 0000-0001-5365-8445
José M BastidaDepartamento de Hematología, IBSAL-Hospital Universitario de Salamanca, Salamanca, Spain.ORCID 0000-0002-8007-3909
José RiveraServicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, Instituto Murciano de Investigación Biosanitaria-Arrixaca, Centro de Investigacién Biomódica en Red de Enfermedades Raras-U765, Murcia, Spain.ORCID 0000-0003-4225-6840
Centro Regional de Hemodonación · ESHospital Universitario Ramón y Cajal · ESConsejo Superior de Investigaciones Científicas · ESUniversity of Perugia · ITComplexo Hospitalario Universitario A Coruña · ESGifu University of Medical Science · JPHospital General De Segovia · ESHospital Virgen de la Salud · ESInstituto de Investigación Biomédica de Salamanca · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

β1-Tubulin plays a major role in proplatelet formation and platelet shape maintenance, and pathogenic variants in TUBB1 lead to thrombocytopenia and platelet anisocytosis (TUBB1-RT). To date, the reported number of pedigrees with TUBB1-RT and of rare TUBB1 variants with experimental demonstration of pathogenicity is limited. Here, we report 9 unrelated families presenting with thrombocytopenia carrying 6 β1-tubulin variants, p.Cys12LeufsTer12, p.Thr107Pro, p.Gln423*, p.Arg359Trp, p.Gly109Glu, and p.Gly269Asp, the last of which novel. Segregation studies showed incomplete penetrance of these variants for platelet traits. Indeed, most carriers showed macrothrombocytopenia, some only increased platelet size, and a minority had no abnormalities. Moreover, only homozygous carriers of the p.Gly109Glu variant displayed macrothrombocytopenia, highlighting the importance of allele burden in the phenotypic expression of TUBB1-RT. The p.Arg359Trp, p.Gly269Asp, and p.Gly109Glu variants deranged β1-tubulin incorporation into the microtubular marginal ring in platelets but had a negligible effect on platelet activation, secretion, or spreading, suggesting that β1-tubulin is dispensable for these processes. Transfection of TUBB1 missense variants in CHO cells altered β1-tubulin incorporation into the microtubular network. In addition, TUBB1 variants markedly impaired proplatelet formation from peripheral blood CD34+ cell-derived megakaryocytes. Our study, using in vitro modeling, molecular characterization, and clinical investigations provides a deeper insight into the pathogenicity of rare TUBB1 variants. These novel data expand the genetic spectrum of TUBB1-RT and highlight a remarkable heterogeneity in its clinical presentation, indicating that allelic burden or combination with other genetic or environmental factors modulate the phenotypic impact of rare TUBB1 variants.

Indexed as

ThrombocytopeniaTubulinBlood PlateletsHumansMegakaryocytesTUBB1 protein, humanTubulin

Identifiers

PMID34516618
PMCPMC8714720
OpenAlexW3201323041

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.